Patents by Inventor Wolfgang Stähle

Wolfgang Stähle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3-substituted cyclopentylamine derivatives
    Patent number: 10118919
    Abstract: Compounds of the formula I in which R, W, R1, R4, X1, X2, X3, X4 and q have the meanings indicated in Claim 1, are inhibitors of fatty acid synthase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: November 6, 2018
    Assignee: Merck Patent GmbH
    Inventors: Christos Tsaklakidis, Wolfgang Staehle, Birgitta Leuthner
  • 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES
    Publication number: 20180022738
    Abstract: Compounds of the formula I in which R, W, R1, R4, X1, X2, X3, X4 and q have the meanings indicated in Claim 1, are inhibitors of fatty acid synthase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
    Type: Application
    Filed: September 6, 2017
    Publication date: January 25, 2018
    Applicant: Merck Patent GmbH
    Inventors: Christos TSAKLAKIDIS, Wolfgang STAEHLE, Birgitta LEUTHNER
  • Piperazine derivatives as FASN inhibitors
    Patent number: 9809552
    Abstract: Compounds of the formula I in which R, X1, X2, X3, X4, R1, R2 and q have the meanings indicated in Claim 1, are inhibitors of fatty acid synthase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: November 7, 2017
    Assignee: MERCK PATENT GMBH
    Inventors: Wolfgang Staehle, Christos Tsaklakidis, Manja Friese-Hamim, Birgitta Leuthner, Dirk Wienke
  • 3-substituted cyclopentylamine derivatives
    Patent number: 9790216
    Abstract: Compounds of the formula I in which R, W, R1, R4, X1, X2, X3, X4 and q have the meanings indicated in claim 1, are inhibitors of fatty acid synthase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: October 17, 2017
    Assignee: Merck Patent GmbH
    Inventors: Christos Tsaklakidis, Wolfgang Staehle, Birgitta Leuthner
  • 3-aminocyclopentane carboxamide derivatives
    Patent number: 9732032
    Abstract: Compounds of the formula I in which R1, R4, R, X1, X2, X3, X4, q and W have the meanings indicated in Claim 1, are inhibitors of fatty acid synthase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: August 15, 2017
    Assignee: MERCK PATENT GMBH
    Inventors: Christos Tsaklakidis, Wolfgang Staehle, Brigitta Leuthner, Paul Czodrowski
  • 1,3-Disubstituted cyclopentane derivatives
    Patent number: 9718785
    Abstract: Compounds of the formula I in which R, Y, R1, X1, X2, X3 and q have the meanings indicated in claim 1, are inhibitors of fatty acid synthase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: August 1, 2017
    Assignee: MERCK PATENT GMBH
    Inventors: Christos Tsaklakidis, Wolfgang Staehle, Birgitta Leuthner, Thomas Fuchss
  • 1,3-diaminocyclopentane carboxamide derivatives
    Patent number: 9670142
    Abstract: Compounds of the formula I in which R1, R4, R6, R, X1, X2, X3, X4, q and W have the meanings indicated in claim 1, are inhibitors of fatty acid synthase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: June 6, 2017
    Assignee: Merck Patent GmbH
    Inventors: Christos Tsaklakidis, Wolfgang Staehle, Birgitta Leuthner, Paul Czodrowski, Thomas Fuchss
  • Benzyl piperidine compounds as lysophosphatidic acid (LPA) receptor antagonist
    Patent number: 9527850
    Abstract: The invention provides novel substituted benzyl piperidine compounds according to Formula (I) as lysophosphatidic acid (LPA) receptor antagonists, their manufacture and use for the treatment of proliferative or inflammatory diseases, such as cancer, fibrosis or arthritis.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: December 27, 2016
    Assignee: Merck Patent GmbH
    Inventors: Kai Schiemann, Wolfgang Staehle, Michael Busch, Dirk Wienke, Oliver Poeschke, Christa Burger
  • PIPERAZINE DERIVATIVES AS FASN INHIBITORS
    Publication number: 20160280655
    Abstract: Compounds of the formula I in which R, X1, X2, X3, X4, R1, R2 and q have the meanings indicated in Claim 1, are inhibitors of fatty acid synthase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
    Type: Application
    Filed: February 24, 2014
    Publication date: September 29, 2016
    Applicant: MERCK PATENT GMBH
    Inventors: Wolfgang STAEHLE, Christos TSAKLAKIDIS, Manja FRIESE-HAMIM, Birgitta LEUTHNER, Dirk WIENKE
  • Piperidine and piperazine derivatives as autotaxin inhibitors
    Patent number: 9452997
    Abstract: The present invention relates to piperidine and pyrazine derivatives according to formulae (Ia), (Ib) and (II) as autotaxin inhibitors and the use of such compounds for the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by increased lysophosphatic acid levels and/or the activation of autotaxin, in particular of different cancers.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: September 27, 2016
    Assignee: MERCK PATENT GMBH
    Inventors: Kai Schiemann, Melanie Schultz, Wolfgang Staehle
  • 3-AMINOCYCLOPENTANE CARBOXAMIDE DERIVATIVES
    Publication number: 20160264517
    Abstract: Compounds of the formula I in which R1, R4, R, X1, X2, X3, X4, q and W have the meanings indicated in Claim 1, are inhibitors of fatty acid synthase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
    Type: Application
    Filed: October 17, 2013
    Publication date: September 15, 2016
    Applicant: MERCK PATENT GMBH
    Inventors: Christos TSAKLAKIDIS, Wolfgang STAEHLE, Brigitta LEUTHNER, Paul CZODROWSKI
  • Hydropyrrolopyrrole derivatives for use as fatty acid synthase inhibitors
    Patent number: 9416133
    Abstract: Compounds of the formula I in which R1, R2, R, X1, X2, X3, X4, n1, n2, n3 and n4 have the meanings indicated in claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: August 16, 2016
    Assignee: MERCK PATENT GMBH
    Inventors: Wolfgang Staehle, Christos Tsaklakidis, Birgitta Leuthner, Dirk Wienke, Frank Czauderna, Ansgar Wegener
  • 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES
    Publication number: 20160200714
    Abstract: Compounds of the formula I in which R, W, R1, R4, X1, X2, X3, X4 and q have the meanings indicated in claim 1, are inhibitors of fatty acid synthase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
    Type: Application
    Filed: May 12, 2014
    Publication date: July 14, 2016
    Applicant: Merck Patent GmbH
    Inventors: Christos TSAKLAKIDIS, Wolfgang STAEHLE, Birgitta LEUTHNER
  • 1,3-DISUBSTITUTED CYCLOPENTANE DERIVATIVES
    Publication number: 20160176824
    Abstract: Compounds of the formula I in which R, Y, R1, X1, X2, X3 and q have the meanings indicated in claim 1, are inhibitors of fatty acid synthase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
    Type: Application
    Filed: July 11, 2014
    Publication date: June 23, 2016
    Applicant: MERCK PATENT GMBH
    Inventors: Christos TSAKLAKIDIS, Wolfgang STAEHLE, Birgitta LEUTHNER, Thomas FUCHSS
  • 1,3-DIAMINOCYCLOPENTANE CARBOXAMIDE DERIVATIVES
    Publication number: 20160130214
    Abstract: Compounds of the formula I in which R1, R4, R6, R, X1, X2, X3, X4, q and W have the meanings indicated in claim 1, are inhibitors of fatty acid synthase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
    Type: Application
    Filed: May 9, 2014
    Publication date: May 12, 2016
    Applicant: Merck Patent GmbH
    Inventors: Christos TSAKLAKIDIS, Wolfgang STAEHLE, Birgitta LEUTHNER, Paul CZODROWSKI, Thomas FUCHSS
  • Pyrido-pyrimidine derivatives
    Patent number: 9283225
    Abstract: Compounds of the formula I in which Het, R3 and R4 have the meanings indicated in Claim 1, are inhibitors of RON and can be employed, for the treatment of cancer.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: March 15, 2016
    Assignee: Merck Patent GmbH
    Inventors: Wolfgang Staehle, Oliver Schadt, Christine Knuehl, Manja Friese-Hamim, Bayard R. Huck, Andreas Goutopoulos, Nadia Brugger
  • Thiazole derivatives
    Patent number: 9249114
    Abstract: Compounds of the formula I in which R, R1, X and Y have the meanings indicated in Claim 1, are inhibitors of TBK1 and IKK? and can be employed, inter alia, for the treatment of cancer and inflammatory diseases.
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: February 2, 2016
    Assignee: Merck Patent GmbH
    Inventors: Srinivasa R. Karra, Wolfgang Staehle, Eike Staub, Margarita Wucherer-Plietker
  • HYDROPYRROLOPYRROLE DERIVATIVES FOR USE AS FATTY ACID SYNTHASE INHIBITORS
    Publication number: 20150252046
    Abstract: Compounds of the formula I in which R1, R2, R, X1, X2, X3, X4, n1, n2, n3 and n4 have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
    Type: Application
    Filed: August 30, 2013
    Publication date: September 10, 2015
    Applicant: MERCK PATENT GMBH
    Inventors: Wolfgang Staehle, Christos Tsaklakidis, Birgitta Leuthner, Dirk Wienke, Frank Czauderna, Ansgar Wegener
  • Pyrazolopyridinone derivatives as LPA receptor antagonists
    Patent number: 9067938
    Abstract: The present invention relates to novel pyrazolopyridinone derivatives according to formula (I) and a process of manufacturing thereof. These pyrazolopyridinone derivatives can be used as LPA receptor antagonists for the treatment of various herein disclosed diseases.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: June 30, 2015
    Assignee: Merck Patent GmbH
    Inventors: Kai Schiemann, Wolfgang Staehle, Sr., Dirk Wienke
  • Benzonaphthyridinamines as autotaxin inhibitors
    Patent number: 9029387
    Abstract: The present invention relates to benzonaphthyridinamines of the formula (I) as autotaxin inhibitors and to the use thereof in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions in which the inhibition, regulation and/or modulation of phosphodiesterase or lysophospholipase autotaxin plays a role, in particular of various types of cancer and autoimmune and inflammatory diseases.
    Type: Grant
    Filed: February 28, 2011
    Date of Patent: May 12, 2015
    Assignee: Merck Patent GmbH
    Inventors: Wolfgang Staehle, Melanie Schultz, Kai Schiemann